FSN Capital to acquire a majority stake in Epista Life Science.

FSN Capital, a private equity firm, agreed to acquire a majority stake in Epista Life Science, an IT consultancy firm. Financial terms are not disclosed. “We strongly believe that Epista is the foremost consultancy within our area of expertise. With this talent comes an obligation to drive the highest level of positive impact in the Life Science industry. We are pleased to have FSN Capital as our partner for the journey ahead. They’re a sophisticated investor with significant experience scaling IT services companies. This will help us reach our goal of making a positive impact on a global scale faster and more forcefully. We look forward to getting started," Klavs Esbjerg, Epista CEO.